Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
RATIONALE: N-Acetylcysteine (NAC) is currently under investigation as an adjunctive treatment for schizophrenia. The therapeutic potential of NAC may involve modulation of brain glutamate function, but its effects on brain glutamate levels in schizophrenia have not been evaluated. OBJECTIVES: The aim of this study was to examine whether a single dose of NAC can alter brain glutamate levels. A secondary aim was to characterise its effects on regional brain perfusion. METHODS: In a double-blind placebo-controlled crossover study, 19 patients with a diagnosis of schizophrenia underwent two MRI scans, following oral administration of 2400 mg NAC or matching placebo. Proton magnetic resonance spectroscopy was used to investigate the effect of NAC on glutamate and Glx (glutamate plus glutamine) levels scaled to creatine (Cr) in the anterior cingulate cortex (ACC) and in the right caudate nucleus. Pulsed continuous arterial spin labelling was used to assess the effects of NAC on resting cerebral blood flow (rCBF) in the same regions. RESULTS: Relative to the placebo condition, the NAC condition was associated with lower levels of Glx/Cr, in the ACC (P < 0.05), but not in the caudate nucleus. There were no significant differences in CBF in the NAC compared to placebo condition. CONCLUSIONS: These data provide preliminary evidence that NAC can modulate ACC glutamate in patients with schizophrenia. In contrast, physiological effects of NAC on the brain were not detectable as between session changes in rCBF. Future studies assessing the effects of a course of treatment with NAC on glutamate metabolites in schizophrenia are indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“…such as phencyclidine or ketamine, produce effects that resemble the symptoms of schizophrenia inman (Javitt and Zukin 1991; Krystal et al. 1994) and increase glutamate metabolite levels in frontal cortical brain areas (Moghaddam et al. 1997; Rowland 2005; Stone et al. 2012; Javitt et al. 2018).”
BackgroundNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Self-citationMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
The promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Stone, J. M., Dietrich, C., Edden, R., Mehta, M. A., De Simoni, S., Reed, L. J., Krystal, J. H., Nutt, D., & Barker, G. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.171 · Cited by 295
Self-citationMoghaddam, B., & Krystal, J. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs075 · Cited by 238
Cited by
N-Acetylcysteine (NAC): Impacts on Human Health
Tenório, M. C. D. S., Graciliano, N. G., Moura, F. A., Oliveira, A. C. M. D., & Goulart, M. O. F. (2021) · Antioxidants · doi:10.3390/antiox10060967 · Cited by 526
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders
Bradlow, R. C. J., Berk, M., Kalivas, P. W., Back, S. E., & Kanaan, R. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00907-3 · Cited by 87
Smiley, C. E., Saleh, H. K., Nimchuk, K. E., Garcia-Keller, C., & Gass, J. T. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113517 · Cited by 15
Metadata
- Authors
- McQueen, G., Lally, J., Collier, T., Zelaya, F., Lythgoe, D. J., Barker, G. J., Stone, J. M., McGuire, P., MacCabe, J. H., & Egerton, A.
- Venue
- Psychopharmacology
- Published
- 2018-08-23
- Volume
- 235
- Issue
- 10
- Pages
- 3045-3054
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2888654824
- Cited by
- 35
- References
- 15
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. https://app.cochat.ai/papers/10.1007/s00213-018-4997-2
- The paper
- McQueen, G., Lally, J., Collier, T., Zelaya, F., Lythgoe, D. J., Barker, G. J., Stone, J. M., McGuire, P., MacCabe, J. H., & Egerton, A. (2018). Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. Psychopharmacology. https://doi.org/10.1007/s00213-018-4997-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.